Leo Pharma

This study tested a drug called tralokinumab in 28 children aged 6 to 12 with moderate-to-severe eczema. The goal was to see how the drug moves through the body and if it is safe and effective. Children received injections over many weeks and used moisturizer daily. The drug aims…

This study looked at whether a higher dose of the drug brodalumab works better than the standard dose for people with moderate-to-severe plaque psoriasis who weigh over 120 kg. A total of 385 adults took part. The main goal was to see if more people achieved at least 90% clearer …

This study tested an ointment called TMB-001 in 153 people aged 6 and older with a rare, inherited skin condition that causes thick, scaly skin (ichthyosis). Participants applied the ointment daily for 12 weeks, and doctors measured improvements in scaling and cracking. The goal …

This study tested a drug called tralokinumab for people with moderate-to-severe atopic hand eczema that hasn't improved with standard treatments. 235 adults received either the drug or a placebo every two weeks for 16 weeks, then everyone got the drug for another 16 weeks. The go…

This study tested a new medicine called LEO 138559 (also known as Temtokibart) in 262 adults with moderate-to-severe eczema. Participants received one of four doses of the drug or a placebo as injections under the skin for 16 weeks. The goal was to see if the drug safely reduces …

This study tested a new ointment (LEO 90100) against a standard one (Daivobet) in 604 Chinese adults with stable plaque psoriasis. Participants applied the treatment for 4 weeks. The goal was to see which ointment better cleared or nearly cleared psoriasis patches on the body.

This early-phase study tested a single injection of a new drug, LEO 158968, in 6 adults experiencing a gout flare (sudden joint pain and swelling). The main goal was to see if the drug could reduce pain to none or mild within a few days. Researchers measured pain using a simple 0…

This study tested a cream called delgocitinib in teens aged 12 to 17 with moderate to severe chronic hand eczema that hasn't responded well to standard steroid creams. For 16 weeks, participants applied the cream or a placebo twice daily. The goal was to see if the cream could cl…

This study tested a new ointment (LEO 124249) for people with chronic hand eczema that hasn't been well controlled with steroid creams. 91 participants applied the ointment twice daily for up to 8 weeks. The goal was to see if it could clear or nearly clear the eczema compared to…

This study tested a cream called delgocitinib, applied twice daily, in 362 Chinese adults and adolescents (ages 12-17) with moderate to severe chronic hand eczema. The goal was to see if the cream could clear or nearly clear the eczema and reduce itch compared to a cream without …

This study looked at whether delgocitinib, taken as a capsule, changes heart rhythms in 40 healthy adults. Researchers compared the drug to a placebo using detailed ECG recordings. The goal was to check for any heart-related safety issues, not to treat a disease.

This early-stage study tested whether delgocitinib cream, a treatment for skin conditions like eczema, can cause skin irritation when exposed to light. Thirty-five healthy adults received a single application of the cream and a placebo on different skin spots, then were exposed t…

This study looked at how much of the drug tacrolimus enters the bloodstream when applied as a cream to healthy skin. Twenty-four healthy adults applied the cream twice daily for 14 days. The goal was to measure drug levels and check for side effects, not to treat any disease.

This early-stage study tested a new compound called LEO 158968 in 120 healthy adults aged 18 to 60. The goal was to see what side effects it might cause, how well it is tolerated, and how the body processes it. Participants received either the drug or a placebo, and researchers m…

This study looked at how the drug tralokinumab behaves in the body when given as one injection versus two injections. It involved 101 healthy adults aged 18 to 55. The goal was to compare the drug levels and safety of the two injection methods, not to treat any disease.

This study tested whether delgocitinib cream, applied to the skin and then exposed to UV light, can cause a photoallergic reaction. Sixty healthy adults aged 18-64 with fair to medium skin types took part. Researchers compared skin reactions between areas with the cream and areas…

This study tested a new drug called LEO 153339 in 108 healthy adults to see if it is safe and how the body handles it. Participants received either the drug or a placebo, and stayed in the clinic for up to 12 days for monitoring. The goal was to check for side effects and measure…